Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198095701> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W3198095701 endingPage "65" @default.
- W3198095701 startingPage "60" @default.
- W3198095701 abstract "Background - Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump inhibitors that has recently been approved by the FDA and European Union for treatment of acid-related diseases. Objectives - To assess the efficacy and tolerability of rabeprazole 20 mg in actual conditions of use in everyday clinical practice on subjects with diagnosis of erosive gastroesophageal reflux disease and/or gastric and/or duodenal ulcer. Patients/Methods - A total of 171 outpatients (55% men, 45% women) with a mean age of 42.5 years were enrolled in this trial. The majority of subjects (81.0%) were Caucasians. Patients with endoscopically confirmed erosive/ulcerative gastroesophageal reflux disease (Savary-Miller classification), duodenal ulcer and/or benign gastric ulcer were eligible to receive rabeprazole 20 mg once daily for 4 to 8 weeks, depending on the diagnosis and at investigators' discretion. Patients were requested to record their symptoms in a diary card in a daily basis. Results - One hundred and sixty two patients completed the study in accordance with the protocol. Reflux esophagitis was diagnosed in 78 (48.1%) patients, duodenal ulcer in 39 (24.1%) and gastric ulcer in 24 (14.8%). Eleven (6.8%) patients presented reflux esophagitis associated with duodenal ulcer and 7 (4.3%) associated with gastric ulcer. Finally, 3 (1.9%) presented both gastric and duodenal ulcer. Fifty-three percentage of patients were free of symptoms on the first day of treatment and 89.5% after a week. The healing rate was 84.4 % for patients with reflux esophagitis, 90.6% for duodenal ulcer and 90.9% for gastric ulcer. The adverse effects were minimal and transitory. Conclusions - Rabeprazole is highly effective and well tolerated in acute healing of reflux esophagitis and peptic ulcers. In adittion, it provides fast symptoms relief ." @default.
- W3198095701 created "2021-09-13" @default.
- W3198095701 creator A5019011891 @default.
- W3198095701 creator A5022589714 @default.
- W3198095701 creator A5028918061 @default.
- W3198095701 creator A5031073880 @default.
- W3198095701 creator A5044936380 @default.
- W3198095701 creator A5088440425 @default.
- W3198095701 date "2002-03-01" @default.
- W3198095701 modified "2023-09-27" @default.
- W3198095701 title "Efficacy, safety and tolerability of rabeprazole in treatment of acid-peptic diseases" @default.
- W3198095701 hasPublicationYear "2002" @default.
- W3198095701 type Work @default.
- W3198095701 sameAs 3198095701 @default.
- W3198095701 citedByCount "0" @default.
- W3198095701 crossrefType "journal-article" @default.
- W3198095701 hasAuthorship W3198095701A5019011891 @default.
- W3198095701 hasAuthorship W3198095701A5022589714 @default.
- W3198095701 hasAuthorship W3198095701A5028918061 @default.
- W3198095701 hasAuthorship W3198095701A5031073880 @default.
- W3198095701 hasAuthorship W3198095701A5044936380 @default.
- W3198095701 hasAuthorship W3198095701A5088440425 @default.
- W3198095701 hasBestOaLocation W31980957011 @default.
- W3198095701 hasConcept C126322002 @default.
- W3198095701 hasConcept C197934379 @default.
- W3198095701 hasConcept C2776462128 @default.
- W3198095701 hasConcept C2778375690 @default.
- W3198095701 hasConcept C2779116819 @default.
- W3198095701 hasConcept C2779134260 @default.
- W3198095701 hasConcept C2779920096 @default.
- W3198095701 hasConcept C2781025758 @default.
- W3198095701 hasConcept C2909576783 @default.
- W3198095701 hasConcept C43270747 @default.
- W3198095701 hasConcept C71924100 @default.
- W3198095701 hasConcept C90924648 @default.
- W3198095701 hasConceptScore W3198095701C126322002 @default.
- W3198095701 hasConceptScore W3198095701C197934379 @default.
- W3198095701 hasConceptScore W3198095701C2776462128 @default.
- W3198095701 hasConceptScore W3198095701C2778375690 @default.
- W3198095701 hasConceptScore W3198095701C2779116819 @default.
- W3198095701 hasConceptScore W3198095701C2779134260 @default.
- W3198095701 hasConceptScore W3198095701C2779920096 @default.
- W3198095701 hasConceptScore W3198095701C2781025758 @default.
- W3198095701 hasConceptScore W3198095701C2909576783 @default.
- W3198095701 hasConceptScore W3198095701C43270747 @default.
- W3198095701 hasConceptScore W3198095701C71924100 @default.
- W3198095701 hasConceptScore W3198095701C90924648 @default.
- W3198095701 hasIssue "1" @default.
- W3198095701 hasLocation W31980957011 @default.
- W3198095701 hasLocation W31980957012 @default.
- W3198095701 hasOpenAccess W3198095701 @default.
- W3198095701 hasPrimaryLocation W31980957011 @default.
- W3198095701 hasRelatedWork W1978893371 @default.
- W3198095701 hasRelatedWork W2029264425 @default.
- W3198095701 hasRelatedWork W2043126354 @default.
- W3198095701 hasRelatedWork W2058077371 @default.
- W3198095701 hasRelatedWork W2070862781 @default.
- W3198095701 hasRelatedWork W2301212622 @default.
- W3198095701 hasRelatedWork W2322754744 @default.
- W3198095701 hasRelatedWork W2399407524 @default.
- W3198095701 hasRelatedWork W2403473070 @default.
- W3198095701 hasRelatedWork W2403906477 @default.
- W3198095701 hasRelatedWork W2407757568 @default.
- W3198095701 hasRelatedWork W2411998895 @default.
- W3198095701 hasRelatedWork W2434578536 @default.
- W3198095701 hasRelatedWork W2438768280 @default.
- W3198095701 hasRelatedWork W2473587340 @default.
- W3198095701 hasRelatedWork W2612667235 @default.
- W3198095701 hasRelatedWork W3024902120 @default.
- W3198095701 hasRelatedWork W2478738222 @default.
- W3198095701 hasRelatedWork W2846296922 @default.
- W3198095701 hasRelatedWork W3013887484 @default.
- W3198095701 hasVolume "39" @default.
- W3198095701 isParatext "false" @default.
- W3198095701 isRetracted "false" @default.
- W3198095701 magId "3198095701" @default.
- W3198095701 workType "article" @default.